

Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the June 1, 2018 Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at www.ab.bluecross.ca/dbl/publications.html

Please refer to the June 1, 2018 Updates for complete listings of: products available by special authorization, products available by restricted benefit / special authorization, products with changes to criteria for coverage, restricted benefits, added products, new established interchangeable groupings, products with a price change and discontinued listings.

Please note that the online *Interactive Drug Benefit List (iDBL)* at www.ab.bluecross.ca/dbl/idbl_main1.html is a near real-time application, and as such, contains the most up-to-date information.

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Sandoz Canada Inc. that the shortage of Sandoz Fenofibrate S 160 mg Tablet (DIN 02288052) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 21, 2018**.

FENOFIBRATE

160 MG CAPSULE / TABLET

00002246860	APO-FENO-SUPER (TABLET)	APX	\$ 0.2723
00002288052	SANDOZ FENOFIBRATE S (TABLET)	SDZ	\$ 0.2723
00002241602	LIPIDIL SUPRA (TABLET)	BGP	\$ 1.3092

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage of Novo-Clobazam 10 mg Tablet (DIN 02238334) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 22, 2018**.

CLOBAZAM

10 MG TABLET

00002238334	NOVO-CLOBAZAM	TEV	\$ 0.1210
00002244638	APO-CLOBAZAM	APX	\$ 0.2197

... continued from previous page

Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of pms-Hydrochlorothiazide 12.5 mg Tablet (DIN 02274086) manufactured by Pharmascience Inc., Apo-Hydro 12.5 mg Tablet (DIN 02327856) manufactured by Apotex Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Pharmascience Inc. has advised Alberta Blue Cross that the shortage of pms-Hydrochlorothiazide 12.5 mg Tablet (DIN 02274086) has been resolved.

As a result, Apo-Hydro 12.5 mg Tablet (DIN 02327856) will no longer be considered a temporary benefit for the *ADBL* after **June 25, 2018**.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)

FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.744 2018/05

